Exelixis (EXEL) Competitors $44.86 -0.31 (-0.69%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$44.78 -0.09 (-0.19%) As of 08:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXEL vs. ALNY, BIIB, UTHR, INCY, NBIX, BMRN, EXAS, RGEN, HALO, and IONSShould you be buying Exelixis stock or one of its competitors? The main competitors of Exelixis include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. Exelixis vs. Its Competitors Alnylam Pharmaceuticals Biogen United Therapeutics Incyte Neurocrine Biosciences BioMarin Pharmaceutical Exact Sciences Repligen Halozyme Therapeutics Ionis Pharmaceuticals Alnylam Pharmaceuticals (NASDAQ:ALNY) and Exelixis (NASDAQ:EXEL) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership. Does the media refer more to ALNY or EXEL? In the previous week, Exelixis had 3 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 22 mentions for Exelixis and 19 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.15 beat Exelixis' score of 0.74 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 10 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Which has higher valuation & earnings, ALNY or EXEL? Exelixis has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.25B18.27-$278.16M-$2.09-150.69Exelixis$2.17B5.64$521.27M$2.2020.39 Which has more volatility and risk, ALNY or EXEL? Alnylam Pharmaceuticals has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Is ALNY or EXEL more profitable? Exelixis has a net margin of 27.99% compared to Alnylam Pharmaceuticals' net margin of -11.49%. Exelixis' return on equity of 28.81% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-11.49% -510.31% -6.48% Exelixis 27.99%28.81%21.94% Do analysts rate ALNY or EXEL? Alnylam Pharmaceuticals currently has a consensus target price of $345.70, indicating a potential upside of 9.77%. Exelixis has a consensus target price of $44.72, indicating a potential downside of 0.31%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Exelixis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.80Exelixis 2 Sell rating(s) 7 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.48 Do insiders and institutionals believe in ALNY or EXEL? 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 1.2% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 2.9% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryExelixis beats Alnylam Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXEL vs. The Competition Export to ExcelMetricExelixisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.23B$2.93B$5.54B$9.07BDividend YieldN/A2.43%5.06%4.03%P/E Ratio20.3920.9928.2420.33Price / Sales5.64252.01389.0187.48Price / Cash23.2941.0526.2427.98Price / Book5.717.638.115.50Net Income$521.27M-$55.05M$3.19B$250.38M7 Day Performance1.59%7.11%3.69%2.19%1 Month Performance7.86%8.14%7.69%10.92%1 Year Performance100.27%1.62%29.36%16.41% Exelixis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXELExelixis4.7914 of 5 stars$44.86-0.7%$44.72-0.3%+100.3%$12.23B$2.17B20.391,147ALNYAlnylam Pharmaceuticals4.174 of 5 stars$324.13-2.3%$341.91+5.5%+20.9%$42.26B$2.25B-155.092,230Positive NewsAnalyst ForecastBIIBBiogen4.7882 of 5 stars$130.13-2.1%$188.48+44.8%-41.7%$19.07B$9.68B12.857,605Trending NewsAnalyst RevisionUTHRUnited Therapeutics4.9895 of 5 stars$290.39-1.4%$386.15+33.0%-8.0%$13.10B$2.88B11.591,305Positive NewsINCYIncyte4.6844 of 5 stars$67.27-1.7%$74.53+10.8%+7.7%$13.02B$4.24B210.232,617NBIXNeurocrine Biosciences4.5328 of 5 stars$127.88-1.0%$162.00+26.7%-9.5%$12.66B$2.36B43.351,800Trending NewsInsider TradeAnalyst RevisionBMRNBioMarin Pharmaceutical4.945 of 5 stars$57.41-0.2%$93.61+63.1%-31.7%$11.01B$2.85B21.343,040Positive NewsEXASExact Sciences4.7703 of 5 stars$52.48-1.6%$70.40+34.1%+12.0%$9.90B$2.76B-9.527,000RGENRepligen4.6008 of 5 stars$124.43-2.4%$172.83+38.9%+3.4%$6.99B$634.44M-276.511,778Positive NewsHALOHalozyme Therapeutics4.8282 of 5 stars$54.22+0.4%$61.90+14.2%+7.5%$6.68B$1.02B14.42390IONSIonis Pharmaceuticals4.5817 of 5 stars$41.78-2.8%$58.25+39.4%-13.1%$6.65B$705M-13.971,069 Related Companies and Tools Related Companies Alnylam Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives BioMarin Pharmaceutical Alternatives Exact Sciences Alternatives Repligen Alternatives Halozyme Therapeutics Alternatives Ionis Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXEL) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exelixis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
